<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214278</url>
  </required_header>
  <id_info>
    <org_study_id>GWLUH-002</org_study_id>
    <secondary_id>GWLUH2010</secondary_id>
    <nct_id>NCT01214278</nct_id>
  </id_info>
  <brief_title>Bioavailability of Different n-3 Fatty Acid Formulations</brief_title>
  <official_title>Relative Bioavailability of Different n-3 Fatty Acid Formulations in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gottfried Wilhelm Leibniz Universität Hannover</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gottfried Wilhelm Leibniz Universität Hannover</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine differences in short term bioavailability between four&#xD;
      n-3 FA formulations in healthy males.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-chain n-3 fatty acids (n-3 FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid&#xD;
      (DHA) are known to positively affect the lipid profile, vascular tone and blood coagulation.&#xD;
      Moreover, EPA and DHA possess anti-inflammatory effects and play a central role in the&#xD;
      functioning of the brain and central nervous system. Therefore, an increased EPA and DHA&#xD;
      intake is highly recommend. However, it is unknown whether different chemical formulations of&#xD;
      EPA + DHA rich supplements (re-esterified triglycerides, ethyl-esters, phospholipids) have&#xD;
      identical bioavailability. The objective of this study is to examine differences in short&#xD;
      term bioavailability between four n-3 FA formulations:&#xD;
&#xD;
        -  Supplement 1: EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil uncoated&#xD;
           capsules&#xD;
&#xD;
        -  Supplement 2: EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules&#xD;
           (GArTG)&#xD;
&#xD;
        -  Supplement 3: EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules&#xD;
&#xD;
        -  Supplement 4: DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL)&#xD;
&#xD;
      The study preparations are certificated supplements and available on the market.&#xD;
&#xD;
      There are no comparative investigations, which analyzed the bioavailability of these four n-3&#xD;
      FA formulations in a similar design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under concentration time curve (AUC)</measure>
    <time_frame>about 24 hours</time_frame>
    <description>Concentration of eicosapentanoiec acid (EPA) and docosahexanoiec acid (DHA) was measured at baseline and after 2, 4, 6, 8 and 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under concentration time curve (AUC)</measure>
    <time_frame>about 48 and 72 hours</time_frame>
    <description>Concentration of eicosapentanoiec acid (EPA) and docosahexanoiec acid (DHA) was measured at baseline and after 2, 4, 6, 8, 24, 48 and 72 hours.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Health</condition>
  <arm_group>
    <arm_group_label>Supplement 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil uncoated capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rTG</intervention_name>
    <description>EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)</description>
    <arm_group_label>Supplement 1</arm_group_label>
    <other_name>re-esterified triglycerides</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GArTG</intervention_name>
    <description>EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)</description>
    <arm_group_label>Supplement 2</arm_group_label>
    <other_name>rTG in gastric acid resistant capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE</intervention_name>
    <description>EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)</description>
    <arm_group_label>Supplement 3</arm_group_label>
    <other_name>ethylesters</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPL</intervention_name>
    <description>DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)</description>
    <arm_group_label>Supplement 4</arm_group_label>
    <other_name>phospholipids from krill-oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  males,&#xD;
&#xD;
          -  20-50 years,&#xD;
&#xD;
          -  Caucasian,&#xD;
&#xD;
          -  healthy,&#xD;
&#xD;
          -  body mass index (BMI) 20-28 kg/m²,&#xD;
&#xD;
          -  no medical treatment,&#xD;
&#xD;
          -  written confirmation of the subjects after detailed spoken and written explanation&#xD;
             about the study contents,&#xD;
&#xD;
          -  ability and willingness of the participants to attend the investigator's orders&#xD;
             (compliance of the study conditions, consumption of the study drugs according to the&#xD;
             dosage commendation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  medical treatment (especially corticosteroids, anti-inflammatory drugs, blood lipids&#xD;
             lowering drugs (e.g. statines, fibrates, bile acid exchanger resin, phytosterols)&#xD;
&#xD;
          -  taking any supplements with n-3 FAs, phytosterols, polyglucosamines (Chitosan) or&#xD;
             other lipid binding ingredients&#xD;
&#xD;
          -  daily consumption of n-3 FAs rich fish (salmon, mackerel, herring)&#xD;
&#xD;
          -  heavy chronic diseases (tumors, diabetes typ 1, etc.), documented heart disease,&#xD;
             documented blood clotting disorders, renal failure, liver diseases&#xD;
&#xD;
          -  documented blood clotting disorders and consumption of coagulation-inhibiting drugs&#xD;
             (for example Marcumar, ASS)&#xD;
&#xD;
          -  allergy or intolerance to fish/fish oil or any of the study ingredients of the test&#xD;
             products&#xD;
&#xD;
          -  chronic gastro-intestinal diseases (Colitis ulcerosa, Morbus Crohn, pancreatic&#xD;
             insufficiency)&#xD;
&#xD;
          -  donation of blood in the last 6 weeks&#xD;
&#xD;
          -  routine consumption of laxative&#xD;
&#xD;
          -  alcohol-, drug- and/or medicament dependence&#xD;
&#xD;
          -  subjects who are not in agreement with the study conditions&#xD;
&#xD;
          -  refusal or rather reset of the consent from the subject&#xD;
&#xD;
          -  active participation in other investigational drug or device trial within the last 30&#xD;
             days&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Hahn, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Gottfried Wilhelm Leibniz University of Hanover</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gottfried Wilhelm leibniz University of Hanover</name>
      <address>
        <city>Hanover</city>
        <state>Lower Saxony</state>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.nutrition.uni-hannover.de</url>
    <description>web page of the institute</description>
  </link>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <last_update_submitted>December 6, 2011</last_update_submitted>
  <last_update_submitted_qc>December 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gottfried Wilhelm Leibniz Universität Hannover</investigator_affiliation>
    <investigator_full_name>M. Sc. Simone Schmidt</investigator_full_name>
    <investigator_title>Master of Science</investigator_title>
  </responsible_party>
  <keyword>bioavailability</keyword>
  <keyword>marine n-3 fatty acids</keyword>
  <keyword>EPA</keyword>
  <keyword>DHA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

